Detalles de la búsqueda
1.
Health-related quality of life and neurocognitive functioning in patients with recurrent glioblastoma treated with intracerebral immune checkpoint inhibition.
J Neurooncol
; 168(1): 159-169, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38502281
2.
Current "state of the art" on dendritic cell-based cancer vaccines in melanoma.
Curr Opin Oncol
; 35(2): 87-93, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36721893
3.
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022).
J Transl Med
; 21(1): 488, 2023 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37475035
4.
Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights.
Curr Opin Oncol
; 34(2): 115-122, 2022 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35050937
5.
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
J Transl Med
; 20(1): 391, 2022 09 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36058945
6.
Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1+ Myeloid Dendritic Cells.
Int J Mol Sci
; 23(9)2022 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-35563257
7.
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy).
J Transl Med
; 19(1): 278, 2021 06 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34193182
8.
Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report.
BMC Ophthalmol
; 21(1): 250, 2021 Jun 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34090381
9.
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases.
Cancer Immunol Immunother
; 69(12): 2589-2598, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32591862
10.
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
Lancet Oncol
; 20(9): 1239-1251, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31345627
11.
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.
J Transl Med
; 17(1): 303, 2019 09 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31488153
12.
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Lancet
; 390(10105): 1853-1862, 2017 Oct 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-28822576
13.
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
N Engl J Med
; 372(26): 2521-32, 2015 Jun 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-25891173
14.
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.
Lancet Oncol
; 18(4): 464-472, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28268064
15.
Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system.
Histopathology
; 70(2): 253-263, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27496355
16.
Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.
Cancer Immunol Immunother
; 65(6): 727-40, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27098427
17.
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.
J Transl Med
; 14: 95, 2016 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-27095081
18.
Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.
J Transl Med
; 14(1): 232, 2016 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27484791
19.
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol
; 16(4): 375-84, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25795410
20.
Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases.
Cancer Immunol Immunother
; 64(3): 381-8, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25548092